Abstract
In order to understand microglial senescence it is important to also understand neuroinflammation because the distinction between senescent and activated microglia is a fine one to make and not always made easily. Indeed, it is not easy to reliably identify activated microglia which is why we spend some effort here discussing intricacies associated with both acute and chronic neuroinflammation before addressing the subject of microglial senescence. The idea of microglial senescence in the context of aging-related neurodegenerative disease (NDD) pathogenesis represents a relatively recent idea that emerged largely because of the many caveats and inconsistencies found to be associated with the belief that neuroinflammation is a critical event in NDD pathogenesis. In this paper, we discuss most of these discrepancies and explain why microglial senescence can provide a better conceptual framework for understanding NDD mechanisms and for devising radically different pharmacological approaches to treatment.
Keywords: Neuroinflammation, neurodegenerative disease, microglial activation, microglial dystrophy, Alzheimer’s disease.
CNS & Neurological Disorders - Drug Targets
Title:Microglial Senescence
Volume: 12 Issue: 6
Author(s): Wolfgang J. Streit and Qing-Shan Xue
Affiliation:
Keywords: Neuroinflammation, neurodegenerative disease, microglial activation, microglial dystrophy, Alzheimer’s disease.
Abstract: In order to understand microglial senescence it is important to also understand neuroinflammation because the distinction between senescent and activated microglia is a fine one to make and not always made easily. Indeed, it is not easy to reliably identify activated microglia which is why we spend some effort here discussing intricacies associated with both acute and chronic neuroinflammation before addressing the subject of microglial senescence. The idea of microglial senescence in the context of aging-related neurodegenerative disease (NDD) pathogenesis represents a relatively recent idea that emerged largely because of the many caveats and inconsistencies found to be associated with the belief that neuroinflammation is a critical event in NDD pathogenesis. In this paper, we discuss most of these discrepancies and explain why microglial senescence can provide a better conceptual framework for understanding NDD mechanisms and for devising radically different pharmacological approaches to treatment.
Export Options
About this article
Cite this article as:
Streit J. Wolfgang and Xue Qing-Shan, Microglial Senescence, CNS & Neurological Disorders - Drug Targets 2013; 12 (6) . https://dx.doi.org/10.2174/18715273113126660176
DOI https://dx.doi.org/10.2174/18715273113126660176 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
14-3-3 Protein in CSF Reflects SIV-Mediated Pre-Synaptic Damage
Current HIV Research Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design Peptide-based Vaccines in the Treatment of Specific Allergy
Current Drug Targets - Inflammation & Allergy Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Atopic Dermatitis and Cytokines: The Immunoregulatory and Therapeutic Implications of Cytokines in Atopic Dermatitis - Part II: Negative Regulation and Cytokine Therapy in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Viral Infection - A Cure for Type 1 Diabetes?
Current Medicinal Chemistry Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges
Current Immunology Reviews (Discontinued) A Translational View of Peptide Treatment of Neurological Disorders
Current Medicinal Chemistry Notch Signaling in the Central Nervous System with Special Reference to its Expression in Microglia
CNS & Neurological Disorders - Drug Targets Selection of Microbial T-Cell Epitopes for Immune-Diagnosis, Immune- Therapy and Vaccine Design
Current Pharmacogenomics QSAR Study on a Series of Aryl Carboxylic Acid Amide Derivatives as Potential Inhibitors of Dihydroorotate Dehydrogenase (DHODH)
Medicinal Chemistry Therapeutic Strategies in Autoimmune Diseases by Interfering with Leukocyte Endothelium Interaction
Current Pharmaceutical Design The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Oxidative stress and myocarditis
Current Pharmaceutical Design Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Mouse Models of Autoimmune Diseases
Current Drug Discovery Technologies